- Home
- ACAD vs CDP Comparison
ACAD vs CDP Comparison
Compare ACAD & CDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- CDP
- Stock Information
- Founded
- ACAD 1993
- CDP 1988
- Country
- ACAD United States
- CDP United States
- Employees
- ACAD N/A
- CDP N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- CDP Real Estate Investment Trusts
- Sector
- ACAD Health Care
- CDP Real Estate
- Exchange
- ACAD Nasdaq
- CDP Nasdaq
- Market Cap
- ACAD 3.8B
- CDP 3.3B
- IPO Year
- ACAD 2004
- CDP N/A
- Fundamental
- Price
- ACAD $20.98
- CDP $28.26
- Analyst Decision
- ACAD Buy
- CDP Buy
- Analyst Count
- ACAD 18
- CDP 6
- Target Price
- ACAD $27.71
- CDP $33.50
- AVG Volume (30 Days)
- ACAD 2.1M
- CDP 874.0K
- Earning Date
- ACAD 08-05-2025
- CDP 07-28-2025
- Dividend Yield
- ACAD N/A
- CDP 4.33%
- EPS Growth
- ACAD N/A
- CDP N/A
- EPS
- ACAD 1.37
- CDP 1.24
- Revenue
- ACAD $996,283,000.00
- CDP $748,556,000.00
- Revenue This Year
- ACAD $13.39
- CDP N/A
- Revenue Next Year
- ACAD $10.59
- CDP $5.84
- P/E Ratio
- ACAD $15.33
- CDP $22.72
- Revenue Growth
- ACAD 22.42
- CDP 5.34
- 52 Week Low
- ACAD $13.40
- CDP $23.92
- 52 Week High
- ACAD $25.23
- CDP $34.22
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- CDP 51.05
- Support Level
- ACAD $20.75
- CDP $27.95
- Resistance Level
- ACAD $23.09
- CDP $28.64
- Average True Range (ATR)
- ACAD 0.78
- CDP 0.51
- MACD
- ACAD -0.20
- CDP -0.05
- Stochastic Oscillator
- ACAD 9.83
- CDP 47.57
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About CDP COPT Defense Properties of Beneficial Interest
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.